Pranata Raymond, Tondas Alexander Edo, Yonas Emir, Chintya Veresa, Yamin Muhammad
Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Sriwijaya, Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia.
Indian Pacing Electrophysiol J. 2019 Nov-Dec;19(6):216-221. doi: 10.1016/j.ipej.2019.09.005. Epub 2019 Sep 18.
Prevalence of atrial fibrillation (AF) in patients with congenital heart disease (CHD) is on the rise. Anti-arrhythmic drugs are usually the first line of treatment in CHD, however, it is often ineffective and poorly tolerated. We aimed to perform a systematic review to assess the efficacy and safety of catheter ablation for AF in CHD.
We performed a comprehensive search on catheter ablation for atrial fibrillation in congenital heart disease up until July 2019 through several electronic databases.
Ablation of AF in patients with CHD had a modest 12 months AF freedom ranging from 32.8% to 63%, which can be increased by subsequent/repeat ablation. The complexity of CHD appears to have a significant effect on a study but not in others. Catheter ablation in ASD and persistent left superior vena cava had a high success rate. Overall, catheter ablation is safe whichever the type of CHD is.
Catheter ablation for AF in CHD had modest efficacy that can be increased by subsequent/repeat ablation and it also has an excellent safety profile. Ablation in complex CHD could also have similar efficacy, however, it is preferably done by experts in a high volume tertiary center.
先天性心脏病(CHD)患者心房颤动(AF)的患病率正在上升。抗心律失常药物通常是CHD的一线治疗方法,然而,它往往无效且耐受性差。我们旨在进行一项系统评价,以评估导管消融治疗CHD患者AF的疗效和安全性。
我们通过几个电子数据库对截至2019年7月的先天性心脏病心房颤动导管消融进行了全面检索。
CHD患者AF消融术后12个月无AF的比例为32.8%至63%,可通过后续/重复消融提高。CHD的复杂性似乎对一项研究有显著影响,但对其他研究没有影响。房间隔缺损(ASD)和永存左上腔静脉的导管消融成功率较高。总体而言,无论CHD的类型如何,导管消融都是安全的。
CHD患者AF的导管消融疗效一般,可通过后续/重复消融提高,且安全性良好。复杂CHD的消融也可能有类似疗效,然而,最好由大型三级中心的专家进行。